NGNE · Insider Trading
Neurogene, Inc. Common Stock
Every open-market purchase and sale reported by NGNE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Rachel McMinn | Chief Executive Officer | M | +756 | +$19.14K |
| 2026-07-07 | Christine Mikail Cvijic | President and CFO | Sell | −4,800 | −$173.38K |
| 2026-07-02 | Christine Mikail Cvijic | President and CFO | Sell | −4,800 | −$166.59K |
| 2026-06-16 | Keith Woods | Director | A | +15,400 deriv. | — |
| 2026-06-16 | Keith Woods | Director | A | +12,050 deriv. | — |
| 2026-06-16 | Keith Woods | Director | A | +7,700 deriv. | — |
| 2026-05-08 | Christine Mikail Cvijic | President and CFO | Sell | −9,600 | −$300.04K |
| 2026-05-07 | Christina Shafer | Chief Commercial Officer | A | +120,000 deriv. | — |
| 2026-03-30 | Julie Jordan | Chief Medical Officer | Sell | −828 | −$18.13K |
| 2026-03-30 | Rachel McMinn | Chief Executive Officer | Sell | −3,352 | −$74.00K |
| 2026-03-30 | Christine Mikail Cvijic | President and CFO | Sell | −2,558 | −$55.32K |
| 2026-03-17 | Stuart Cobb | Chief Scientific Officer | Sell | −6,797 | −$141.45K |
| 2026-03-17 | Christine Mikail Cvijic | President and CFO | Sell | −4,045 | −$84.18K |
| 2026-03-03 | Christine Mikail Cvijic | President and CFO | Sell | −4,800 | −$120.53K |
| 2026-02-24 | Stuart Cobb | Chief Scientific Officer | A | +16,500 | — |
| 2026-02-24 | Cory S. Freedland | Director | A | +12,050 deriv. | — |
| 2026-02-24 | Rohan Palekar | Director | A | +12,050 deriv. | — |
| 2026-02-24 | Sarah B. Noonberg | Director | A | +12,050 deriv. | — |
| 2026-02-24 | Keith Woods | Director | A | +12,050 deriv. | — |
| 2026-02-24 | Robert Baffi | Director | A | +12,050 deriv. | — |
| 2026-02-24 | Julie Jordan | Chief Medical Officer | A | +4,900 | — |
| 2026-02-24 | Rachel McMinn | Chief Executive Officer | A | +25,900 | — |
| 2026-02-24 | Christine Mikail Cvijic | President and CFO | A | +22,000 | — |
| 2025-06-13 | Robert Keith Woods | Director | A | +12,050 deriv. | — |
| 2025-06-13 | Sarah B. Noonberg | Director | A | +12,050 deriv. | — |
| 2025-06-13 | Robert Baffi | Director | A | +12,050 deriv. | — |
| 2025-06-13 | Cory S. Freedland | Director | A | +12,050 deriv. | — |
| 2025-06-13 | Rohan Palekar | Director | A | +12,050 deriv. | — |
| 2025-05-15 | Stuart Cobb | Chief Scientific Officer | Sell | −6,797 | −$103.00K |
| 2025-03-28 | Stuart Cobb | Chief Scientific Officer | A | +7,200 | — |
| 2025-03-28 | Julie Jordan | Chief Medical Officer | A | +8,400 | — |
| 2025-03-28 | Christine Mikail Cvijic | President and CFO | A | +20,300 | — |
| 2025-03-28 | Rachel McMinn | Chief Executive Officer | A | +23,900 | — |
| 2025-03-17 | Christine Mikail Cvijic | President and CFO | Sell | −4,501 | −$76.25K |
| 2024-11-27 | Samsara BioCapital, L.P. | 10%+ Owner | Buy | +146,310 | +$3.78M |
| 2024-11-25 | Christine Mikail Cvijic | President and CFO | Buy | +24,000 | +$491.40K |
| 2024-11-25 | Rachel McMinn | Chief Executive Officer | Buy | +47,500 | +$969.00K |
| 2024-06-17 | Sarah B. Noonberg | Director | A | +7,700 deriv. | — |
| 2024-06-17 | Cory S. Freedland | Director | A | +7,700 deriv. | — |
| 2024-06-17 | Rohan Palekar | Director | A | +7,700 deriv. | — |
| 2024-06-17 | Robert Keith Woods | Director | A | +7,700 deriv. | — |
| 2024-06-17 | Robert Baffi | Director | A | +7,700 deriv. | — |
| 2024-03-14 | Stuart Cobb | Chief Scientific Officer | A | +20,391 | — |
| 2024-03-14 | Rachel McMinn | Chief Executive Officer | A | +93,282 deriv. | — |
| 2024-03-14 | Christine Mikail Cvijic | President and CFO | A | +31,903 | — |
| 2024-01-18 | Robert Baffi | Director | A | +15,400 deriv. | — |
| 2024-01-18 | Julie Jordan | Chief Medical Officer | A | +75,000 deriv. | — |
| 2024-01-18 | Robert Keith Woods | Director | A | +15,400 deriv. | — |
| 2024-01-18 | Cory S. Freedland | Director | A | +15,400 deriv. | — |
| 2024-01-18 | Sarah B. Noonberg | Director | A | +15,400 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Samsara BioCapital, L.P. | 10%+ Owner | 1,717,127 | $40.42M |
| Rachel McMinn | Chief Executive Officer | 1,345,063 | $31.66M |
| Christine Mikail Cvijic | President and CFO | 88,240 | $2.08M |
| Stuart Cobb | Chief Scientific Officer | 33,303 | $783.95K |
| Julie Jordan | Chief Medical Officer | 12,472 | $293.59K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NGNE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.